NCT02146261View on ClinicalTrials.gov

A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

April 30, 2014

Conditions
Healthy
Interventions
DRUG

E6011

Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)

DRUG

Placebo

Subcutaneous administration of placebo

Trial Locations (1)

Unknown

Sagamihara

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02146261 - A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter